A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy

September 29, 2026
10:59 pm

In a study published in Cancer Discovery, cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells.

Alena Gros, Ph.D., is the senior author of the study and group leader of the Tumor Immunology and Immunotherapy Group at the Vall d’Hebron Institute of Oncology (VHIO) in Spain. Andrea Garcia-Garijo, Ph.D., is a postdoctoral fellow in Gros’ group and first author of the study.

“Neoantigens, which are proteins produced by cancer cells, make tumors easily recognizable to the immune system, prompting it to mount an immune response against the cancer cells expressing these neoantigens,” said Gros.

A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy

In a study published in Cancer Discovery, cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells.

Sign up for Blog Updates